Όλο το DSpace

Εμφάνιση απλής εγγραφής

Is locally advanced head-neck cancer one more candidate for accelerated hypofractionation?

dc.creatorKOUKOURAKIS I.M., ZYGOGIANNI A., KOULOULIAS V., KYRGIAS G., PANTELIADOU M., NANOS C., ABATZOGLOU I., KOUKOURAKIS M.I.en
dc.date.accessioned2023-01-31T08:45:15Z
dc.date.available2023-01-31T08:45:15Z
dc.date.issued2021
dc.identifier10.21873/anticanres.14797
dc.identifier.issn02507005
dc.identifier.urihttp://hdl.handle.net/11615/75279
dc.description.abstractBackground/Aim: Hypofractionated accelerated radiotherapy (HypoAR) is widely applied for the treatment of early laryngeal cancer. Its role in locally advanced head-neck cancer (LA-HNC) is unexplored. Patients and Methods: We present results of a prospective trial on 124 patients with LAHNC, treated with radio-chemotherapy with three different HypoAR fractionations (3.5 Gy/day × 14-15 fractions, 2.7 Gy/day × 20-21 fractions, and 2.5 Gy/day × 21-22 fractions). Results: Protraction of the overall treatment time due to oropharyngeal mucositis was enforced in 18/57 laryngeal, 6/19 nasopharyngeal, and 15/48 cancer patients with other tumors. Regarding late toxicities, laryngeal edema grade 3 was noted in 5/57 patients with laryngeal cancer, while severe dysphagia was noted in 4/124 and tracheoesophageal fistula formation in 1/124 patients. The complete response rates obtained were 73%, 84%, and 67% in patients with laryngeal, nasopharyngeal, and other tumors, respectively. The 3-year locoregional progression-free survival was 58%, 73%, and 55%, respectively. Conclusion: HypoAR chemoradiotherapy is feasible, with acceptable early and late radiotherapy toxicities, response rates and LPFS. © 2021 International Institute of Anticancer Research. All rights reserved.en
dc.language.isoenen
dc.sourceAnticancer Researchen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85099701615&doi=10.21873%2fanticanres.14797&partnerID=40&md5=788a7d52cd7c7758045beddfd1958f04
dc.subjectamifostineen
dc.subjectcetuximaben
dc.subjectchlorhexidineen
dc.subjectcisplatinen
dc.subjectcodeine phosphateen
dc.subjectdocetaxelen
dc.subjectfluorouracilen
dc.subjectmouthwashen
dc.subjectparacetamolen
dc.subjectposaconazoleen
dc.subjectacute toxicityen
dc.subjectadenocarcinomaen
dc.subjectadulten
dc.subjectadvanced canceren
dc.subjectageden
dc.subjectanalgesiaen
dc.subjectanaplastic carcinomaen
dc.subjectArticleen
dc.subjectcancer combination chemotherapyen
dc.subjectcancer patienten
dc.subjectcancer radiotherapyen
dc.subjectcancer survivalen
dc.subjectchemoradiotherapyen
dc.subjectclinical target volumeen
dc.subjectcomputer assisted tomographyen
dc.subjectconformal radiotherapyen
dc.subjectcontrolled clinical trialen
dc.subjectcontrolled studyen
dc.subjectdysphagiaen
dc.subjectfemaleen
dc.subjectfollow upen
dc.subjectgross tumor volumeen
dc.subjecthead and neck canceren
dc.subjecthead and neck squamous cell carcinomaen
dc.subjecthumanen
dc.subjecthypofractionated accelerated radiotherapyen
dc.subjecthypofractionated radiotherapyen
dc.subjecthypopharynx canceren
dc.subjectimage guided radiotherapyen
dc.subjectinduction chemotherapyen
dc.subjectintensity modulated radiation therapyen
dc.subjectlarynx canceren
dc.subjectlarynx carcinomaen
dc.subjectlarynx edemaen
dc.subjectlocal disease free survivalen
dc.subjectlocal progression free survivalen
dc.subjectmajor clinical studyen
dc.subjectmaleen
dc.subjectmouth canceren
dc.subjectmouth hygieneen
dc.subjectmucosa inflammationen
dc.subjectmultiple cycle treatmenten
dc.subjectmycosisen
dc.subjectnasopharynx canceren
dc.subjectneck canceren
dc.subjectorgans at risken
dc.subjectoropharynxen
dc.subjectoropharynx canceren
dc.subjectpharyngitisen
dc.subjectphysical examinationen
dc.subjectplanning target volumeen
dc.subjectprimary tumoren
dc.subjectpriority journalen
dc.subjectprogression free survivalen
dc.subjectprospective studyen
dc.subjectradiation dose fractionationen
dc.subjectradiation injuryen
dc.subjectradiation responseen
dc.subjectradiotherapy dosageen
dc.subjectsarcomaen
dc.subjectswallowingen
dc.subjecttherapy delayen
dc.subjecttooth brushingen
dc.subjecttracheoesophageal fistulaen
dc.subjecttreatment durationen
dc.subjectvolumetric modulated arc therapyen
dc.subjectadverse eventen
dc.subjectcancer stagingen
dc.subjecthead and neck tumoren
dc.subjectintensity modulated radiation therapyen
dc.subjectKaplan Meier methoden
dc.subjectmetastasisen
dc.subjectmiddle ageden
dc.subjectmortalityen
dc.subjectmultimodality cancer therapyen
dc.subjectpathologyen
dc.subjectproceduresen
dc.subjectprognosisen
dc.subjecttreatment outcomeen
dc.subjectvery elderlyen
dc.subjectyoung adulten
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectChemoradiotherapyen
dc.subjectCombined Modality Therapyen
dc.subjectDose Fractionation, Radiationen
dc.subjectFemaleen
dc.subjectHead and Neck Neoplasmsen
dc.subjectHumansen
dc.subjectKaplan-Meier Estimateen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectNeoplasm Metastasisen
dc.subjectNeoplasm Stagingen
dc.subjectPrognosisen
dc.subjectRadiation Dose Hypofractionationen
dc.subjectRadiotherapy Dosageen
dc.subjectRadiotherapy, Intensity-Modulateden
dc.subjectTreatment Outcomeen
dc.subjectYoung Adulten
dc.subjectInternational Institute of Anticancer Researchen
dc.titleIs locally advanced head-neck cancer one more candidate for accelerated hypofractionation?en
dc.typejournalArticleen


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής